Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
-
Total Revenue for Q1 2020 was approximately $617,000 (excluding Curetis Revenue)Curetis and Ares revenue was approximately $900,000 for the first quarter generating a pro forma combined unaudited...
-
GAITHERSBURG, Md., April 27, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first...
-
- Investigator initiated study at Sweden’s Karolinska Institutet to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections - Rapid diagnostic tests are viewed as...
-
Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species and 21...
-
Total Revenue for Q1 2020 was approximately $617,000 (excluding first quarter 2020 Curetis Revenue)Balance sheet strengthened significantly with $13.9 million cash raised in Q1 2020OpGen and Curetis...
-
Following strong support from shareholders, OpGen and Curetis consummated their business combination transaction Curetis business now wholly owned by OpGen Inc. as parent company New leadership team...
-
Vote approving transaction passes with 95% support for the transaction Closing expected in the coming days GAITHERSBURG, Md., March 30, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN,...
-
Quorum achieved for OpGen stockholder vote on Curetis business combination with 99% of votes supporting transactionTransaction close anticipated by early April 2020Combined OpGen and Curetis business...
-
Shareholder proxy vote achieves quorum with 99% support for the transaction Final step in OpGen / Curetis business combination achieved pending results of Special Meeting GAITHERSBURG, Md., March ...